LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

TG Therapeutics Inc

Cerrado

SectorSanidad

32.14 -0.65

Resumen

Variación precio

24h

Actual

Mínimo

31.54

Máximo

32.55

Métricas clave

By Trading Economics

Ingresos

23M

28M

Ventas

20M

141M

P/B

Media del Sector

85.211

35.664

Margen de beneficios

19.97

Empleados

370

EBITDA

25M

38M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+0.65% upside

Dividendos

By Dow Jones

Próximas Ganancias

3 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

578M

5.1B

Apertura anterior

32.79

Cierre anterior

32.14

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

102 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

TG Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2025, 22:41 UTC

Principales Movimientos del Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept 2025, 16:04 UTC

Principales Movimientos del Mercado

Upexi Shares Climb on Solana Gains

12 sept 2025, 15:03 UTC

Principales Movimientos del Mercado

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 20:09 UTC

Ganancias

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept 2025, 19:23 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:16 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:03 UTC

Charlas de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept 2025, 18:59 UTC

Charlas de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept 2025, 18:38 UTC

Charlas de Mercado
Ganancias

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept 2025, 18:33 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept 2025, 18:22 UTC

Charlas de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept 2025, 16:56 UTC

Charlas de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept 2025, 16:22 UTC

Ganancias

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 16:19 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

12 sept 2025, 16:11 UTC

Ganancias

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept 2025, 15:37 UTC

Charlas de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept 2025, 15:22 UTC

Charlas de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept 2025, 15:07 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept 2025, 14:34 UTC

Charlas de Mercado

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sept 2025, 14:10 UTC

Charlas de Mercado

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sept 2025, 13:58 UTC

Charlas de Mercado

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sept 2025, 13:58 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sept 2025, 13:57 UTC

Ganancias

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sept 2025, 13:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 sept 2025, 13:56 UTC

Charlas de Mercado

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sept 2025, 13:54 UTC

Charlas de Mercado

U.S. Natural Gas Recovers Ground -- Market Talk

Comparación entre iguales

Cambio de precio

TG Therapeutics Inc previsión

Precio Objetivo

By TipRanks

0.65% repunte

Estimación a 12 Meses

Media 32.67 USD  0.65%

Máximo 50 USD

Mínimo 11 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TG Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

1

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 34.86Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

102 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat